Targeting Fear of Cancer Recurrence in Cancer Survivors: Evaluation of Internet-Based Emotional Freedom Techniques and Internet-Based Mindfulness Meditation as Intervention Strategies

Inclusion Criteria

• •Patients should have reached a minimum age of 18 years at the time of enrolment
• •Patients should have a histologically confirmed diagnosis of a solid cancer or haematologic malignancy
• •Patients should have completed surgery, chemotherapy, radiation therapy, immunotherapy, hormone therapy, targeted drug therapy or a combination of these at least 2 months ago and no longer than 5 years ago at the time of enrolment
• •Patients should have an expected life expectancy of at least 5 years
• •Patients are disease-free at the time of enrolment, as defined by the absence of somatic disease activity parameters
• •Patients can be included in a stable phase of their immunotherapy (e.g. adjuvant use of checkpoint inhibitors for melanoma), hormonal therapy (e.g. for breast and prostate cancer), targeted drug therapy (e.g. trastuzumab and pertuzumab for breast cancer; stable dose of PARP inhibitors for ovarian cancer; retuximab for lymphoma), or a combination of these
• •Patients must suffer from high FCR based on the Cancer Worry Scale (cut-off ≥ 14)
• •Patients should be able to adequately communicate in Dutch
• •Patients should present with a sufficient mental and physical functional status (according to investigator's judgment and first baseline assessment) for completing the questionnaires and neuropsychological assessment
• •Patients under current treatment for a depression or anxiety disorder are allowed to enrol provided their depression or anxiety disorder is stable